Literatúra

  1. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al. The metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Book Co.1995;1279–1327.
  2. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985;371–31.
  3. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.
  4. Rašlová K, Smolková B, Frohlich JJ, et al. Methylentetrahydrofolate reductase genotypes in young survivors of myocardial infarction. Atherosclerosis 1997;134:167.
  5. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180–1188.
  6. Egerton W, Silberberg J, Crooks R, et al. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996;77:759–61.
  7. Duell BP, Malinow RM. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipid 1997;8:28–34.
  8. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. European concerted action project. JAMA 1997;277:1775–1781.
  9. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low density lipoprotein by homocysteine thilactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 1994;4:70–77.
  10. Harker LA, Ross R. Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:431–441.
  11. Graeber JE, Slott JH, Ulane RE, et al. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982;16:490–493.
  12. Di Minno G, Davi C, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400–1406.
  13. von Eckardstein A, Malinow MR, Malinow MR, Upson B. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:960–964.
  14. Palareti G, Coccheri S. Lowered antithrombin III activity and other cloting changes in homocystinuria: effects of pyridoxine-folate regiment. Haemostasis 1989;19:24–28.
  15. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909–1916.
  16. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895–901.
  17. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759–762.
  18. Olszewki AJ, McCully KS. Homocysteine metabolism and oxidative modification of proteins and lipids. Free Rad Biol Med 1993;14:683–693.
  19. Toborek M, Kopieczna-Grzebieniak E, Drozdz M, Wieczorek M. Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis 1995;115:217–224.
  20. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980;18:113–121.
  21. Harker LA, Harlen JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced indothelial injury and atherosclerosis in baboons. Circ Res 1983;53:731–739.
  22. Tsai J-C, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6389–6373.
  23. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997;157:2299–2308.
  24. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994;106:9–19.
  25. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552–561.
  26. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35–41.
  27. Van den Berg M, Stehouwer DA, Bierdrager E, et al. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996;16:165–171.
  28. Selhub J, Jaques F, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286–291.
  29. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–881.
  30. Arnesen E, Refsum H, Bonaa KH, et al. The Tromso study: a population based prospective study of serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704–709.
  31. Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25:1924–1930.
  32. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concetration and risk of stroke in middle-aged British men. Lancet 1995;346:1395–1398.
  33. Nygard O, Vollset EV, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995;274:1526–1533.
  34. Malinow MR, Nieto FJ, Szklo M, et al. Carotidal artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation 1993;87:1107–1113.
  35. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996, 94:2410–2416.
  36. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulfide. Eur J Clin Invest 1979;9:301–307.
  37. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2698.
  38. Van der Mooren MJ, Wouters MGAJ, Blom HJ, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-736.
  39. Štatistická ročenka Slovenskej republiky, Bratislava: Veda, vydavateľstvo SAV 1998:726.
  40. Zborník referátových príspevkov z konferencie „Výživa-potraviny-legislatíva“, Bratislava: Slovenská spoločnosť pre výživu 1998:214.
  41. Swain RA, Clair LS. The role of folic acid in deficiency states and prevention of disease. J Fam Pract 1997;44:138–144.
  42. FAO/WHO Expert Group. Requirements of vitamin A, folate and vitamin B12. Geneva, Switzerland: FAO/WHO 1987:117.
  43. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1932–1835.
  44. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce number of cases of spina bifida and other neural tube defects. MMWR 1992;41:1–7.
  45. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998,97:138–141.
  46. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Tromb 1994;14:465–470.
  47. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–1933.
  48. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Intern Med 1998,15:1301–1306.
  49. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009–1015.
  50. Oakley GP Jr. Let’s increase folic acid fortification and include vitamin B12. Am J Clin Nutr 1997;65:1889–1890.
  51. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449–1454.
  52. Zimmermann MB, Shane B. Supplemental folic acid. Am J Clin Nutr 1993;58:127–128.
  53. Allen RH, Stabler SP, Savage DG, et al. Diagnosis of cobalamin deficiency: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol 1990;34:90–98.
  54. Ellenbogen L, Cooper BA. Vitamin B-12. In: Handbook of Vitamins (Machlin LJ, ed.), 2nd ed. New York, NY: Marcel Dekker 1991:491–536.
  55. Dudman NPB, Wilcken DEL, Wanig J, et al. Disordered methionine/homocysteine metabolism in premature vascular disease: its occurrence, cofactor therapy, and enzymology. Arterioscler Tromb 1993;13:1253–1260.
  56. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149–1155.